Does BCBS SC Cover Wegovy? Plans, Medicare, and Appeals

Most BlueCross BlueShield of South Carolina plans do not cover Wegovy. The insurer classifies it as an anti-obesity agent, and the majority of its commercial and ACA Marketplace plans exclude weight-loss medications outright. That exclusion holds even when a doctor prescribes Wegovy for its FDA-approved cardiovascular use, because BCBS SC bases coverage on how a drug is classified, not on the diagnosis written on the prescription.¹

Whether you can get Wegovy paid for comes down to the plan your employer bought or the plan you picked on the Marketplace. A narrow set of employer groups have added weight-loss drugs as an optional benefit; everyone else is looking at an appeal, a manufacturer savings program, or paying cash.

Check Your Specific Plan First

Coverage varies by plan design, so start by confirming what your plan actually excludes. BCBS SC tells members to contact their HR department or review their benefit documents to see whether weight-loss medications are included or excluded.² The My Health Toolkit member portal also displays formulary details and claims status.³

If your plan does cover Wegovy, prior authorization is still required before the pharmacy can fill it.⁴

Why the Cardiovascular Approval Doesn’t Change the Answer

In March 2024, the FDA expanded Wegovy’s approved uses to include reducing the risk of cardiovascular death, heart attack, and stroke in adults with established cardiovascular disease who are overweight or obese.⁵ That approval has not changed how BCBS SC handles the drug. The insurer has stated that coverage rests on “drug classification, not specific indication,” so Wegovy remains subject to any weight-loss exclusion in the member’s plan regardless of whether it is prescribed for obesity, cardiovascular risk reduction, or obstructive sleep apnea.⁴

The One Commercial Exception: Employer-Elected Coverage

There is a single pathway for commercial coverage. Self-funded employer groups that use the insurer’s Lowest Net Cost (LNC) formulary can add weight-loss drug coverage as an optional benefit category. When a group elects it, all drugs in the weight-loss category become covered for its employees, including Wegovy, Zepbound, Saxenda, Qsymia, and Contrave.⁶

This is the employer’s decision, not the employee’s, and it is all or nothing. If your employer declined, no appeal or doctor’s letter will get Wegovy covered for weight loss under that plan. Even when the benefit is elected, prior authorization still applies.⁴

If You Have BlueChoice HealthPlan

BlueChoice HealthPlan, an affiliate within the BCBS SC family, takes a stricter position. It states that weight-loss medications are typically not covered, and that it will not cover GLP-1 medications for weight loss even when a member’s plan includes a weight-loss drug benefit, because the plan treats GLP-1s as not FDA-approved for that purpose. Any GLP-1 coverage requires prior authorization documentation showing a Type 2 diabetes diagnosis.⁷

BlueChoice also requires that patients have tried and failed metformin or a metformin combination product for at least 90 days before a GLP-1 will be authorized.⁸

If You’re on the State Employee Plan

The South Carolina State Health Plan, which covers more than 540,000 public employees, spouses, and dependents, does not cover anti-obesity medications. GLP-1 drugs are covered only for Type 2 diabetes. Even that limited coverage has been expensive; the plan spent $106.4 million (after rebates) on GLP-1 prescriptions for diabetes between January and September 2024.⁹

Rather than expanding coverage, the Public Employee Benefit Authority has tightened it. In 2024, the board approved 30-day fill limits and a new prior authorization process for GLP-1 prescriptions, estimated to save $18 million annually.¹⁰

If You’re on South Carolina Medicaid

South Carolina Medicaid briefly covered GLP-1 weight-loss drugs starting in November 2024.¹¹ That coverage ends January 1, 2026, when the state discontinues coverage for Wegovy and Saxenda when prescribed for obesity.¹² The state cited roughly $7.8 million in combined state and federal spending during the prior fiscal year and the federal government’s rejection of a proposed rule that would have required coverage.¹³ The health department has said it may reconsider as drug prices decline.

If You Have Medicare: The GLP-1 Bridge Program

Federal law prohibits Medicare Part D from covering drugs prescribed for weight loss. CMS has created a time-limited workaround: the Medicare GLP-1 Bridge Program, running from July 1, 2026 through December 31, 2026, which provides eligible Medicare beneficiaries access to Wegovy and Zepbound for weight loss outside of the standard Part D benefit.¹⁴

The program is open to anyone enrolled in a Medicare Advantage plan with drug coverage or a standalone Part D plan. Individual plan sponsors do not need to opt in, because CMS runs the program centrally. Beneficiaries pay a fixed $50 monthly copay, which does not count toward Part D out-of-pocket limits.¹⁵ For BCBS SC Medicare Advantage members, this is a pathway that did not previously exist.

How to Appeal a Denial

If Wegovy is denied, BCBS SC allows members to file a written appeal within 180 days of the date on the Explanation of Benefits. The appeal must include the member’s name, ID number, patient name, claim number, and the name and relationship of the person filing. A Designation of Authorized Representative form is required if someone other than the covered member files.³

An appeal has better odds when the denial is based on medical necessity rather than a flat plan exclusion. A plan exclusion is a contract term, and appeals rarely overturn it. For medical necessity denials, a letter from the prescribing physician documenting weight history, prior failed lifestyle attempts, and obesity-related conditions such as cardiovascular disease or diabetes can support the request.¹⁶ Novo Nordisk provides a sample coverage-request letter on its website that doctors can use to petition an employer’s benefits department directly.¹⁷ After internal appeals are exhausted, an external review through the state may be available.

Paying Without Coverage

Novo Nordisk runs several programs that lower Wegovy’s out-of-pocket cost:

Commercially insured patients whose plan covers Wegovy may pay as little as $25 per month through the Wegovy Savings Offer, with maximum savings of $100 per month. Enrollment is available by texting “SAVE” to 83757.¹⁸
Self-pay patients can buy Wegovy directly through NovoCare Pharmacy at $149 per month for the 1.5 mg and 4 mg doses through August 31, 2026, after which the 4 mg dose rises to $199 per month.¹⁷
New self-pay patients can pay $199 per month for the first two months on the 0.25 mg and 0.5 mg starter doses, then $349 per month, for fills through June 30, 2026.¹⁸

Medicare and Medicaid beneficiaries are generally not eligible for the commercial savings offer. People on ACA Marketplace plans, FEHB plans, and state employee plans are not considered government beneficiaries for this purpose and can participate.¹⁸

1
BlueCross BlueShield of South Carolina. Reminder: GLP-1 Utilization Management
2
BlueCross BlueShield of South Carolina. Pharmacy Benefits – Other Group Plans
3
BlueCross BlueShield of South Carolina. Appeal a Denied Claim
4
BlueCross BlueShield of South Carolina. BlueNews for Providers – May 2025
5
U.S. Food and Drug Administration. FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight
6
BlueCross BlueShield of South Carolina. Optional Drug Coverage List
7
BlueChoice HealthPlan. Weight Loss Coverage
8
BlueChoice HealthPlan. Glucagon-Like Peptide-1 Agents Utilization Management Update
9
SC Daily Gazette. States Consider High Costs, Possible Savings of Covering Weight Loss Drugs for Their Workers
10
South Carolina Public Employee Benefit Authority. Health Care Policy Committee Materials – October 2024
11
KFF Health News. GLP-1 Drugs Weight Loss Obesity Coverage – South Carolina
12
SC Daily Gazette. SC Medicaid Program to Stop Covering Expensive Weight Loss Drugs for Obesity
13
KFF. Medicaid Coverage of and Spending on GLP-1s
14
Centers for Medicare & Medicaid Services. Medicare GLP-1 Bridge
15
Medicare Rights Center. GLP-1 Weight Loss Drug Demonstration Begins July 2026
16
Medical News Today. How to Appeal a Wegovy Denial
17
Wegovy. What to Pay for Wegovy
18
NovoCare. Wegovy Savings Offer